Propranolol and Somatostatin Agonist Therapy Resulting in Symptom Improvement and Stabilization of von Hippel-Lindau-Associated Hemangioblastoma: A Case Report

Maran Ilanchezhian; Reinier Alvarez; Amanda Carbonell; Brigitte C Widemann; Prashant Chittiboina; Jaydira Del Rivero*

1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
2Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
3Developmental Therapeutics Branch, Rare Tumor Initiative, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Abstract

Von Hippel-Lindau disease is an inherited, autosomal dominant tumor predisposition syndrome which leads to susceptibility for developing hemangioblastomas of the central nervous system and retina, as well as other tumor types. No approved systemic therapies exist for this disease. Here, we present a patient diagnosed with Von Hippel-Lindau disease, with central nervous system and retinal hemangioblastomas, treated with propranolol and subsequently with Lanreotide. On both treatments, the patient showed notable symptom improvement. In addition, since starting Lanreotide, the patients hemangioblastoma has remained stable on imaging. Based on the symptom improvement in this patient and other reported findings in the literature, propranolol and somatostatin agonist therapy may have an anti-tumor effect in Von Hippel-Lindau associated hemangioblastomas; however, further investigation is warranted.

keywords: Hemangioblastoma; VHL; Somatostatin agonist; Propranolol; Case report
**Introduction**

Von Hippel-Lindau (VHL) disease is an inherited, autosomal dominant tumor predisposition syndrome caused by germline mutations in the VHL tumor suppressor gene [1,2]. This germline mutation is found in approximately 1 in 36,000 individuals [3]. Affected individuals are susceptible to developing Hemangioblastomas (HBs) of the Central Nervous System (CNS) and retina, Renal Cell Carcinomas (RCCs), endolymphatic sac tumors, pheochromocytomas and pancreatic neuroendocrine tumors [2,4]. Patients with VHL disease can be divided into types 1 and 2, based on the probability of developing pheochromocytoma, with type 2 disease carrying the higher risk of pheochromocytoma [2,5].

Due to the development of a variety of benign and malignant neoplasms, patients have a median survival ranging between 40 and 52 years, the shortest amongst cancer predisposition syndromes [6]. The leading causes of morbidity and mortality in these patients are RCC and CNS HB [7,8]. The treatment for VHL associated RCC and CNS HB is surgery [7]. However, if surgery is not a viable option, there are no approved systemic therapies that have gained widespread use for the treatment of VHL related CNS HB [2,7]. The natural history of VHL-associated CNS HB was described in a recent long-term study of 225 patients with VHL. On that study, 51% of all CNS HB were stable in size during long-term follow-up and 49% of all CNS HB grew. The most common pattern of growth was salatory (72% of growing tumors), followed by exponential (22%) and linear (6%). This led to the understanding that growth rate is necessary to assess the efficacy of surgical vs. nonsurgical therapies [8].

In addition, retinal HBs are typically the most common and earliest presentation of VHL disease [9,10]. They occur in about 50% of VHL patients and are the first tumor to arise in 1 out of 3 cases. Peripheral retinal HBs can be treated with photocoagulation for small tumors and cryotherapy for larger tumors [11]. However, these treatments cannot be used if the tumor is near the optic nerve. In such cases, the common therapeutic approach is surveillance, due to the high risk of damaging the optic nerve [2]. Currently, surgical resection of growing, symptomatic HBs is the only treatment option for these tumors. Despite the improvement in the understanding of the pathophysiology of hemangioblastomas, no effective treatment strategy has demonstrated clinical efficacy in retinal HBs in addition to VHL associated CNS HB.

Propranolol hydrochloride an FDA approved agent, is a synthetic B1 and B2 adrenergic antagonist that has been marketed for over 50 years, and whose safety has been well reported [12]. It is used for the treatment of hypertension, cardiac arrhythmias, and is effective in treating Infantile Hemangiomas (IH) [13,14]. Moreover, VHL associated HBs have similar histologic appearance and pathogenesis to IH. Albinana et. al, showed that propranolol may have efficacy in the treatment of retinal HBs, in a study where 7 patients with retinal HBs showed stable disease over a period of 12 months [15]. In addition, a study by Shepard et. al, showed propranolol activity in vitro models of VHL RCC and CNS HB, in addition to retrospective data suggesting that propranolol may slow HB growth in VHL patients [16].

Furthermore, VHL-HBs patients has shown to have avidity to Somatostatin Receptor (SSTR) agonist agents such as ⁶⁸Ga-DOTATATE positron emission tomography (PET) imaging [17-19]. Neuroendocrine tumors that express SSTRs demonstrate a clinical response to somatostatin analogue therapy [20,21] and this has been demonstrated in VHL related pancreatic neuroendocrine tumors as well [22]. Sizdahkhani et. al, showed that the somatostatin receptor agonist (octreotide) showed efficacy both in-vitro and in off label use in a patient with advanced VHL HB [23], suggesting that it may have potential as a therapy for VHL associated HB. Here we present a case of a patient with VHL-associated CNS HBs and retinal HBs, treated with propranolol and subsequently with Lanreotide. On both treatments, the patient showed notable symptom improvement with pain reduction and optimal sleep quality. In addition, since starting Lanreotide, the patient’s hemangioblastoma remained stable on surveillance scans.

**Case presentation**

A 16-year-old Caucasian male initially presented with impaired vision due to a retinal hemangioblastoma. This was unsuccessfully treated with laser treatment, followed by cryoablation and eventually resulting in the loss of vision in his left eye. Genetic testing revealed a heterozygous cysteine (C) to guanine (G) base change at nucleotide 469 of his VHL gene, resulting in a codon change at position 86 (proline CCC to one for alanine GCC). The mutation was consistent with type 1 VHL.

At the age of 23 years, a left adrenal nodule, measuring about 1.4 cm was noted on Computerized Tomography (CT) imaging. The patient subsequently enrolled on the VHL natural history study at the National Institutes of Health at this time (NCT00005902). The adrenal nodule has been monitored with plasma and/or urine catecholamine and metanephrines measurement, and Meta-Iodobenzylguanidine (MIBG) imaging, both of which have been normal. The patient has not had any history of hypertension during this period. At the age of 28 years, a 1.7cm right kidney solid lesion was noted on CT imaging, which was suggestive of RCC. Over the next 3 years, this right renal lesion grew up to 3cm. He subsequently enrolled on a clinical trial with sunitinib (NCT00330564- “Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow”) at the age of 31. He was treated with 50 mg of sunitinib daily for 28 days, followed by 14 days off. Sunitinib was discontinued after two cycles due to treatment-related adverse events. Subsequently, he underwent a percutaneous cryoablation of the right kidney lesion.

At the age of 39 years, he reported intense midline lower back pain at the time associated with a 3.1 cm HB at the left T10 nerve root (Figure 1A and E). He reported that the pain was especially severe upon movement and taking non-steroidal anti-inflammatory agents as needed. He was started on off-label oral propranolol (220mg daily, dose was calculated as 3 mg/kg/day over three doses based on the indication for IH), which partially improved his pain and required less analgesic medication. However, the lesion continued to grow from 3.1cm to 3.7cm over the following two years (Figure 1B, C, F, G) and a new 8mm lesion initially improved his pain and required less analgesic medication. However, the lesion continued to grow from 3.1cm to 3.7cm over the following two years (Figure 1B, C, F, G) and a new 8mm lesion.

Lanreotide, the patient’s hemangioblastoma remained stable on surveillance scans.
through growth arrest of the disease burden since the beginning on Lanreotide.

33-year-old female with VHL HBs, propranolol was shown to delay the growth of hemangioblastomas and reduced the intensity and frequency of her migraine headache symptoms [25]. In addition, propranolol has shown an apoptotic effect on HB cell in-vitro in multiple studies [16,26,27]. In this patient, the initial improvement in thoracic back pain appeared to be related to the initiation of propranolol.

Ga-DOTATATE imaging for this patient revealed the presence of somatostatin receptors (SSTRs) avidity and somatostatin agonist was considered as a potential treatment. Subsequently, the patient experienced even greater symptom relief after starting on 120mg Lanreotide injections every 28 days. Sizdahkhani et. al, demonstrated that the SSTR agonist octreotide led to tumor vascular infarction in a patient with VHL HBs over a period of 6 months. The same study demonstrated in-vitro apoptosis of VHL-HB cells in a dose-dependent fashion by the BAX -caspase- 3 pathway [23]. Somatostatin agonist therapy, including Lanreotide, have been successfully used for the treatment of other VHL related tumors [22,28]; however, prospective randomized studies are needed to determine its efficacy in the indication of VHL related HBs. Based on the notable tumor improvement in our patient and the findings of Sizdahkhani et. al, we believe somatostatin agonist therapy may have an antitumor effect in VHL related HBs and further investigation is warranted.

In conclusion, somatostatin agonist such as Lanreotide and propranolol may have a role in the treatment of VHL-related HB, however, prospective clinical trials are needed to assess the anti-tumor activity of both agents alone and in combination. In addition, further studies are necessary to identify mechanisms of anti-tumor activity of propranolol and somatostatin agonist in VHL-related tumors.

**Funding**

The research reported in this publication was supported in part by the Center for Cancer Research, National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI) of the National Institutes of Health (NIH) and the Cancer Moonshot InitiativeSM.

**Availability of data and materials**

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

**Authors’ contributions**

MI carried out the literature search and collected the data published. He then worked with the other authors in writing the paper and prepared the original draft.

RA produced the two figures in the manuscript as well as their corresponding figure legends. He also contributed to the preparation and review of the manuscript.

AC is involved with the active management of the patient.

BW worked with the other authors in the preparation and review of the manuscript.

PC is involved with the active management of the patient. He also worked with the other authors in the preparation and review of the manuscript.

JDR is involved with the active management of the patient. She is the corresponding author as well.
All authors have read and approved the final manuscript.

Consent for publication

Written informed consent for publication of clinical details was obtained from the patient.

References